These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36375775)

  • 21. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study.
    Siddiqui NU; Qamar FN; Jurair H; Haque A
    BMC Infect Dis; 2014 Nov; 14():626. PubMed ID: 25430979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymyxin resistance in Klebsiella pneumoniae: multifaceted mechanisms utilized in the presence and absence of the plasmid-encoded phosphoethanolamine transferase gene mcr-1.
    Nang SC; Han ML; Yu HH; Wang J; Torres VVL; Dai C; Velkov T; Harper M; Li J
    J Antimicrob Chemother; 2019 Nov; 74(11):3190-3198. PubMed ID: 31365098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients.
    Liang D; Liang Z; Deng G; Cen A; Luo D; Zhang C; Ni S
    Front Pharmacol; 2023; 14():1122310. PubMed ID: 37063299
    [No Abstract]   [Full Text] [Related]  

  • 24. Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients.
    Li Y; Deng Y; Zhu ZY; Liu YP; Xu P; Li X; Xie YL; Yao HC; Yang L; Zhang BK; Zhou YG
    Front Pharmacol; 2021; 12():727170. PubMed ID: 34512352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
    Labreche MJ; Frei CR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.
    Landersdorfer CB; Wang J; Wirth V; Chen K; Kaye KS; Tsuji BT; Li J; Nation RL
    J Antimicrob Chemother; 2018 Feb; 73(2):462-468. PubMed ID: 29149294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
    Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
    Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.
    Smith NM; Bulman ZP; Sieron AO; Bulitta JB; Holden PN; Nation RL; Li J; Wright GD; Tsuji BT
    J Antimicrob Chemother; 2017 Aug; 72(8):2297-2303. PubMed ID: 28505268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients.
    Pi MY; Cai CJ; Zuo LY; Zheng JT; Zhang ML; Lin XB; Chen X; Zhong GP; Xia YZ
    J Antimicrob Chemother; 2023 Mar; 78(3):792-801. PubMed ID: 36702748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients.
    Avedissian SN; Miglis C; Kubin CJ; Rhodes NJ; Yin MT; Cremers S; Prickett M; Scheetz MH
    Pharmacotherapy; 2018 Jul; 38(7):730-738. PubMed ID: 29800496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models.
    van der Meijden A; Aranzana-Climent V; van der Spek H; de Winter BCM; Couet W; Meletiadis J; Muller AE; van den Berg S
    J Antimicrob Chemother; 2023 Mar; 78(3):832-839. PubMed ID: 36718051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis.
    Crass RL; Al Naimi T; Wen B; Souza E; Murray S; Pai MP; Jia S
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0079221. PubMed ID: 34252297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens.
    Bian X; Liu X; Hu F; Feng M; Chen Y; Bergen PJ; Li J; Li X; Guo Y; Zhang J
    Front Pharmacol; 2021; 12():785893. PubMed ID: 35058776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
    Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
    Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis.
    Wang K; Zhu Y; Xu F; Liu L; Liu L; Shi M; Nie J; Reinhart H; Liu J; Gao Y; Pu X
    Eur J Pharm Sci; 2024 Apr; 195():106713. PubMed ID: 38295963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
    Diep JK; Sharma R; Ellis-Grosse EJ; Abboud CS; Rao GG
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.